Angiotensin-converting enzyme 2 ameliorates renal fibrosis by blocking the activation of mTOR/ERK signaling in apolipoprotein E-deficient mice

Peptides

Volumn 79, Issue , 2016, Pages 49-57

  Chen, Lai Jiang ^a,b   Xu, Ying Le ^a   Song, Bei ^a   Yu, Hui Min ^c   Oudit, Gavin Y ^d   Xu, Ran ^a   Zhang, Zhen Zhou ^a,b   Jin, Hai Yan ^a,e   Chang, Qing ^a   Zhu, Ding Liang ^a,b   Zhong, Jiu Chang ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d UNIVERSITY OF ALBERTA   (Canada)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiotensin converting enzyme 2; Apolipoprotein E; Atherosclerosis; mTOR; Renal fibrosis

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; APOLIPOPROTEIN E; COLLAGEN TYPE 1; FIBRONECTIN; FIBRONECTIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACEBO; PROTEIN KINASE B; RAPAMYCIN; RECOMBINANT ANGIOTENSIN CONVERTING ENZYME 2; RECOMBINANT PROTEIN; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); DIPEPTIDYL CARBOXYPEPTIDASE; MTOR PROTEIN, MOUSE; PEPTIDE FRAGMENT; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; DRUG EFFECT; DRUG MECHANISM; FIBROBLAST; GENE EXPRESSION; GENE INACTIVATION; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY TUBULE; KIDNEY TUBULE DAMAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; SIGNAL TRANSDUCTION; TUBULOINTERSTITIAL FIBROSIS; ANIMAL; C57BL MOUSE; COMPLICATION; ENZYMOLOGY; FIBROSIS; GENETICS; KIDNEY; KIDNEY DISEASES; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANGIOTENSIN I; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; FIBROSIS; KIDNEY; KIDNEY DISEASES; MALE; MAP KINASE SIGNALING SYSTEM; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84977672432     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2016.03.008     Document Type: Article

References (36)

1. [1] Jin, H.Y., Chen, L.J., Zhang, Z.Z., Xu, Y.L., Song, B., Xu, R., Oudit, G.Y., Gao, P.J., Zhu, D.L., Zhong, J.C., Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling. J. Transl. Med., 13, 2015, 255.
2. [2] Torres, K.Z., Abebe, A.B., Chapman, R.W., Schrier, W.E., Braun, T.I., Steinman, F.T., Winklhofer, G., Brosnahan, P.G., Czarnecki, M.C., Hogan, D.C., Miskulin, F.F., Rahbari-Oskoui, J.J., Grantham, P.C., Harris, M.F., Flessner, C.G., Moore, R.D., HALT-PKD Trial Investigators, Angiotensin blockade in late autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371 (2014), 2267–2276.
3. [3] Nobuhiko, A., Suganuma, E., Babaev, V.R., Fogo, A., Swift, L.L., Linton, M.F., Fazio, S., Ichikawa, I., Kon, V., Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 2143–2148.
4. [4] Zhong, J., Basu, R., Guo, D., Chow, F.L., Byrns, S., Schuster, M., Loibner, H., Wang, X.H., Penninger, J.M., Kassiri, Z., Oudit, G.Y., Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122 (2010), 717–728.
5. [5] Zhong, J., Guo, D., Chen, C.B., Wang, W., Schuster, M., Loibner, H., Penninger, J.M., Scholey, J.W., Kassiri, Z., Oudit, G.Y., Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 57 (2011), 314–322.
6. [6] Olivon, V.C., Aires, R.D., Santiago, L.B., Ramalho, L.Z., Cortes, S.F., Lemos, V.S., Mas receptor overexpression increased Ang-(1–7) relaxation response in renovascular hypertensive rat carotid. Peptides 71 (2015), 250–258.
7. [7] Patel, V.B., Zhong, J.C., Fan, D., Basu, R., Morton, J.S., Parajuli, N., McMurtry, M.S., Davidge, S.T., Kassiri, Z., Oudit, G.Y., Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling. Hypertension 64 (2014), 157–164.
8. [8] Haschke, M., Schuster, M., Poglitsch, M., Loibner, H., Salzberg, M., Bruggisser, M., Penninger, J., Krähenbühl, S., Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 52 (2013), 783–792.
9. [9] Reich, H.N., Oudit, G.Y., Penninger, J.M., Scholey, J.W., Herzenberg, A.M., Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 74 (2008), 1610–1616.
10. [10] Stegbauer, J., Potthoff, S.A., Quack, I., Mergia, E., Clasen, T., Friedrich, S., Vonend, O., Woznowski, M., Königshausen, E., Sellin, L., Rump, L.C., Chronic treatment with angiotensin-(1–7) improves renal endothelial dysfunction in apolipoproteinE-deficient mice. Br. J. Pharmacol. 163 (2011), 974–983.
11. [11] Wen, M., Segerer, S., Dantas, M., Brown, P.A., Hudkins, K.L., Goodpaster, T., Kirk, E., LeBoeuf, R.C., Alpers, C.E., Renal injury in apolipoprotein E-deficient mice. Lab. Invest. 82 (2002), 999–1006.
12. [12] Sahara, M., Ikutomi, M., Morita, T., Minami, Y., Nakajima, T., Hirata, Y., Nagai, R., Sata, M., Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation. Cardiovasc. Res. 101 (2014), 236–246.
13. [13] Thomas, M.C., Pickering, R.J., Tsorotes, D., Koitka, A., Sheehy, K., Bernardi, S., Toffoli, B., Nguyen-Huu, T.P., Head, G.A., Fu, Y., Chin-Dusting, J., Cooper, M.E., Tikellis, C., Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res. 107:7 (2010), 888–897.
14. [14] Jin, H.Y., Song, B., Oudit, G.Y., Davidge, S.T., Yu, H.M., Jiang, Y.Y., Gao, P.J., Zhu, D.L., Ning, G., Kassiri, Z., Penninger, J.M., Zhong, J.C., ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS One, 7, 2012, e38502.
15. [15] Song, B., Zhang, Z.Z., Zhong, J.C., Yu, X.Y., Oudit, G.Y., Jin, H.Y., Lu, L., Xu, Y.L., Kassiri, Z., Shen, W.F., Gao, P.J., Zhu, D.L., Loss of angiotensin-converting enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling pathway. Circ. J. 77:12 (2013), 2997–3006.
16. [16] Zhang, Z.Z., Shang, Q.H., Jin, H.Y., Song, B., Oudit, G.Y., Lu, L., Zhou, T., Xu, Y.L., Gao, P.J., Zhu, D.L., Penninger, J.M., Zhong, J.C., Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice. J. Transl. Med., 11, 2013, 229.
17. [17] Lonnemann, G., Shapiro, L., Engler-Blum, G., Müller, G.A., Koch, K.M., Dinarello, C.A., Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int. 47 (1995), 837–844.
18. [18] Chen, G., Chen, H., Wang, C., Peng, Y., Sun, L., Liu, H., Liu, F., Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One, 7, 2012, e33626.
19. [19] Sangaralingham, S.J., Wang, B.H., Huang, L., Kumfu, S., Ichiki, T., Krum, H., Burnett, J.C.Jr., Cardiorenal fibrosis and dysfunction in aging: imbalance in mediators and regulators of collagen. Peptides 16 (2016), 108–114.
20. [20] Chen, L.J., Xu, R., Yu, H.M., Chang, Q., Zhong, J.C., The ACE2/Apelin signaling MicroRNAs, and hypertension. Int. J. Hypertens., 2015, 2015, 896861.
21. [21] Ortiz-Melo, D.I., Gurley, S.B., Angiotensin converting enzyme 2 and the kidney. Curr. Opin. Nephrol. Hypertens. 25 (2016), 59–66.
22. [22] Dias, A.T., Cintra, A.S., Frossard, J.C., Palomino, Z., Casarini, D.E., Gomes, I.B., Balarini, C.M., Gava, A.L., Campagnaro, B.P., Pereira, T.M., Meyrelles, S.S., Vasquez, E.C., Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension. J. Transl. Med., 12, 2014, 250.
23. [23] Zhong, J., Chen, L.J., Zhang, Z.Z., Xu, Y.L., Xu, R., Song, B., Gao, P.J., Zhu, D.L., Oudit, G.Y., 8D.01: effects of angiotensin-converting enzyme 2 on renal oxidative stress levels in apolipoprotein e-deficient mice. J. Hypertens., 33, 2015, e113.
24. [24] Zhong, J.C., Jin, H.Y., Zhang, Z.Z., Chen, L.J., Xu, R., Xu, Y.L., Gao, P.J., Zhu, D.L., GW26-e0102 loss of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in the apolipoprotein E-deficient mice. J. Am. Coll. Cardiol., 66, 2015, C1.
25. [25] Mann, J.F., Gerstein, H.C., Pogue, J., Bosch, J., Yusuf, S., Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 134 (2001), 629–636.
26. [26] Yamamoto, S., Zhong, J., Yancey, P.G., Zuo, Y., Linton, M.F., Fazio, S., Yang, H., Narita, I., Kon, V., Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. Atherosclerosis 242 (2015), 56–64.
27. [27] Rüster, C., Wolf, G., Renin-angiotensin-aldosterone system and progression of renal disease. J. Am. Soc. Nephrol. 17:11 (2006), 2985–2991.
28. [28] Moreira de Macêdo, S., Guimarães, T.A., Feltenberger, J.D., Sousa Santos, S.H., The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides 62 (2014), 189–196.
29. [29] Laplante, M., Sabatini, D.M., mTOR signaling in growth control and disease. Cell 149 (2012), 274–293.
30. [30] Zhu, J., Zheng, C., Chen, J., Luo, J., Su, B., Huang, Y., Su, W., Li, Z., Cui, T., Ghrelin protects human umbilical vein endothelial cells against high glucose-induced apoptosis via mTOR/P70S6K signaling pathway. Peptides 52 (2014), 23–28.
31. [31] Winbanks, L., Grimwood, A., Gasser, I.A., Darby, T.D., Hewitson, G.J., Role of the phosphatidylinositol 3-kinase and mTOR pathways in the regulation of renal fibroblast function and differentiation. Int. J. Biochem. Cell. Biol. 39 (2007), 206–219.
32. [32] Lloberas, N., Cruzado, J.M., Franquesa, M., Herrero-Fresneda, I., Torras, J., Alperovich, G., Rama, I., Vidal, A., Grinyó, J.M., Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J. Am. Soc. Nephrol. 17:5 (2006), 1395–1404.
33. [33] Martinet, W., De Loof, H., De Meyer, G.R., mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis 233:2 (2014), 601–607.
34. [34] Benjamin, D., Colombi, M., Moroni, C., Hall, M.N., Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10:11 (2010), 868–880.
35. [35] Lieberthal, W., Levine, J.S., The role of the mammalian target of rapamycin (mTOR) in renal disease. J. Am. Soc. Nephrol. 20:12 (2009), 2493–2502.
36. [36] Patel, V.B., Takawale, A., Ramprasath, T., Das, S.K., Basu, R., Grant, M.B., Hall, D.A., Kassiri, Z., Oudit, G.Y., Antagonism of angiotensin 1–7 prevents the therapeutic effects of recombinant human ACE2. J. Mol. Med. (Berl.) 93 (2015), 1003–1013.